Quinoline-Antibody Combination Therapy for Immune-Tolerant Sarcoma
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for soft tissue sarcomas, particularly undifferentiated pleomorphic sarcoma, have low efficacy and high recurrence rates, with limited therapeutic options due to tumor immune tolerance and resistance to immunotherapy.
Innovation Solution
A combination therapy using a quinoline derivative, such as anlotinib, in conjunction with antibodies targeting PD-1/PD-L1 or PDGFR-α, optionally with radiation therapy, to enhance anti-tumor immune response and inhibit tyrosine kinase activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immunotherapy alone is used to treat soft tissue sarcoma, then immune response is activated, but tumor immune tolerance prevents effective treatment
Solution Approach 1:
The treatment approach is segmented into two distinct components: a small-molecule tyrosine kinase inhibitor (anlotinib) that addresses immune tolerance through molecular inhibition, and an immune checkpoint inhibitor (antibody) that activates immune response. This segmentation allows each component to target different aspects of the immune-tumor interaction, overcoming the limitation of using immunotherapy alone.
Solution Approach 2:
The patent employs a composite therapeutic strategy combining two different types of agents with distinct mechanisms of action. The small-molecule inhibitor and antibody work synergistically, with the former breaking immune tolerance and the latter enhancing immune activation, creating a more effective composite treatment than either agent alone.
2Productivity
If conventional treatment methods are used for soft tissue sarcoma, then treatment can be administered, but low efficacy and high recurrence rates occur
Solution Approach 1:
The patent introduces tyrosine kinase inhibitors as intermediary agents that block specific molecular pathways involved in tumor progression and immune evasion. These intermediaries mediate between the tumor cells and the immune system, preventing tumor-driven immune suppression and enhancing the overall effectiveness of the combination therapy.
Solution Approach 2:
The treatment approach changes key parameters of tumor biology by inhibiting tyrosine kinase activity, which alters tumor cell behavior, reduces immune tolerance, and modifies the tumor microenvironment. This parameter change enables the immune system to more effectively recognize and eliminate tumor cells, improving both efficacy and reducing recurrence.
3Adaptability or versatility
If single-agent therapy is used, then treatment simplicity is maintained, but limited therapeutic options and resistance develop
Solution Approach 1:
The patent merges two therapeutic agents with complementary mechanisms into a single combination regimen. The small-molecule inhibitor and antibody are administered together, combining their distinct anti-tumor activities to overcome resistance and expand therapeutic options while maintaining a manageable treatment structure.
Solution Approach 2:
The combination therapy approach serves multiple functions simultaneously: it breaks immune tolerance, activates immune response, inhibits tumor angiogenesis, and prevents resistance development. This multi-functionality provides versatile therapeutic options that can address various aspects of soft tissue sarcoma pathophysiology within a unified treatment framework.
Data Source
AI summary
The present invention belongs to the pharmaceutical field, and provides a quinoline derivative and antibody soft tissue sarcoma combination therapy, specifically relating to a use of a therapeutically effective amount of a quinoline derivative compound I or a pharmaceutically acceptable salt thereof in combination with at least one antibody drug in preparing a drug used for treating soft tissue sarcoma. The chemical name of the quinoline derivative compound I is 1-[[[4-(4-fluoro-2-methyl-1H-indol-5-yl)oxy-6-methoxyquinolin-7-yl]oxy]methyl]cyclopropylamine.